

# Eleni Bekiari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2382702/publications.pdf>

Version: 2024-02-01

52  
papers

2,457  
citations

430442

18  
h-index

214527

47  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3196  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 262.	2.0	749
2	Complications of Diabetes 2017. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-4.	1.0	307
3	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 361, k1310.	2.4	294
4	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	2.0	182
5	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
6	Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1744-1755.e11.	2.4	84
7	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	2.2	79
8	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	2.2	71
9	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	1.1	61
10	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	2.2	54
11	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1857-1868.	2.2	44
12	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , 2016, 52, 458-480.	1.1	42
13	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 169, 165.	2.0	38
14	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	2.2	33
15	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 584-592.	1.5	27
16	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 61-67.	1.4	26
17	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2017, 37, 293-298.	1.5	20
18	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 843-851.	0.9	19

#	ARTICLE	IF	CITATIONS
19	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2018, 31, 572-582.	0.4	19
20	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 106-114.	2.2	19
21	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2395-2401.	2.2	18
22	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 822-831.	2.2	17
23	Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. <i>Endocrine</i> , 2017, 56, 485-494.	1.1	15
24	Eosinophilic pneumonia associated with heroin inhalation: a case report. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 178-180.	1.0	13
25	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2016, 7, 36-38.	1.0	13
26	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.	0.8	12
27	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. <i>European Journal of Haematology</i> , 2017, 98, 563-568.	1.1	10
28	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 281-289.	0.9	10
29	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108921.	1.1	10
30	Insulin sensitivity assessment with euglycemic insulin clamp in adult $\beta$ -thalassaemia major patients. <i>European Journal of Haematology</i> , 2007, 79, 526-530.	1.1	8
31	Effect of Epinephrine and Insulin Resistance on Human Monocytes Obtained From Lean and Obese Healthy Participants: A Pilot Study. <i>Angiology</i> , 2011, 62, 38-45.	0.8	8
32	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6893-6906.	1.6	8
33	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , 2020, , 1.	1.3	7
34	Safety And Efficacy Of 4 Years Of Deferasirox Treatment For Sickle Cell Disease Patients. <i>Hemoglobin</i> , 2013, 37, 94-100.	0.4	6
35	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2549-2557.	1.1	6
36	Add-on interventions for the prevention of recurrent <i>Clostridioides Difficile</i> infection: A systematic review and network meta-analysis. <i>Anaerobe</i> , 2021, 71, 102441.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Effect of Glucose and Insulin on Oxidized Low-Density Lipoprotein Phagocytosis by Human Monocytes: A Pilot Study. <i>Angiology</i> , 2011, 62, 163-166.	0.8	5
38	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2017, Volume 12, 1-10.	4.7	5
39	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , 2016, 54, 620-633.	1.1	4
40	Some glucose-lowering drugs reduce risk for major adverse cardiac events. <i>Annals of Internal Medicine</i> , 2020, 173, JC9.	2.0	3
41	Erythrocytosis Secondary to Testosterone Therapy in a Male with Cryptorchidism: A Case Report. <i>International Journal of Gerontology</i> , 2012, 6, 290-291.	0.7	2
42	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. <i>Diabetes Management</i> , 2015, 5, 119-125.	0.5	2
43	Premixed insulin regimens for type 2 diabetes. <i>Endocrine</i> , 2016, 51, 387-389.	1.1	2
44	Meta-analysis of artificial pancreas trials: methodological considerations. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 685.	5.5	2
45	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 241.	2.0	1
46	In type 2 diabetes, weekly semaglutide reduced HbA <sub>1c</sub> and increased weight loss more than weekly exenatide ER. <i>Annals of Internal Medicine</i> , 2018, 168, JC46.	2.0	1
47	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2021, 174, 141.	2.0	1
48	KDIGO made 12 recommendations for managing diabetes with CKD. <i>Annals of Internal Medicine</i> , 2021, 174, JC26.	2.0	1
49	Hemosiderosis and diabetes mellitus in an untransfused patient with hemoglobin H disease and H63D homozygous hereditary hemochromatosis. <i>Diabetes Research and Clinical Practice</i> , 2007, 76, 468-469.	1.1	0
50	Most add-on therapies to metformin have similar effects on HbA <sub>1c</sub> . <i>Evidence-Based Medicine</i> , 2016, 21, 223-223.	0.6	0
51	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	0
52	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. <i>Annals of Internal Medicine</i> , 2020, 173, JC70.	2.0	0